Galmed pharmaceuticals secures new patent grant extending aramchol's patent protection to 2039, strengthening leadership in nash/mash combination therapy

Tel aviv, israel , march 20, 2025 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and gi oncological indications, today announced the grant of a new patent related to its lead compound, aramchol.
GLMD Ratings Summary
GLMD Quant Ranking